Unknown status • Phase II • Stage III, IV • Medical Oncology • Post-Menopausal • Interventional
The following is imported from ClinicalTrials.gov:
The purpose of this Phase II study is to evaluate the efficacy and safety of Continuous Low- Irradiance Photodynamic Therapy (CLIPT) when used with Verteporfin in the treatment of cutaneous metastases of breast cancer for which no curative or significantly palliative therapy exists, including chest wall therapy.
Breast Cancer
Interventional
15 participant
October 20, 2016
18 - 999
both
Verteporfin
Continuous Low-Irradiance Photodynamic Therapy (CLIPT)
Histologically or cytologically confirmed Stage IIIb or IV breast cancer with cutaneous metastases.
Participants receiving any medications or substances that are known to cause photosensitivity (e.g. tetracyclines, sulfonamides, phenothiazines, sulfonylurea hypoglycemic agents, thiazide diuretics, griseofulvin, fluoroquinolones, St. Johns' wort, amiodarone) are ineligible.
Participants who have received prior systemic therapy (chemotherapy or targeted therapy) within 7 days of Study Day 1 or those who have not recovered from clinically significant adverse events due to agents administered more than 7 days earlier. (continuation of the same regimen of HER-2 antibody targeted therapy agents, hormonal therapy and treatment with bisphosphonates or denosumab are permitted)
Participants who are receiving any other investigational agents during the proposed treatment cycle.
Unknown status
15
10/30/2023
Steven J Isakoff, MD PhD
Rogers Sciences Inc.
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
© 2025 Outcomes4Me Inc. All rights reserved.